The Investigation Of Late-Ccouse Hyperfractionated Accelerated Radiation Therapy And Combination Chemotherapy With Paclitaxel For Adenocarcinoma Of Lung

Objective:To investigate the short-term effective rate and toxicity of late-course hyperfractionated accelerated radiation therapy and combination chemotherapy with paclitaxel for adenocarcinoma of lung,To evaluate the advantage and disadvantage of this combined therapy.Methods:Previously untreated 70 patients with histologically/cytologically proven unresectable NSCLC were eligible.They were divided randomly into two groups: Group A(the simple late-course hyperfractionated accelerated radiation therapy) and Group B(late-course hyperfractionated accelerated radiation therapy and combination chemotherapy with paclitaxel).Methods:From June 2007 to December 2008,70 patients with histologically/cytologically proven inoperable Adenocarcinoma of lung were randomized into two groups as the Group A(the simple late-course hyperfractionated accelerated radiation therapy) and Group B(late-course hyperfractionated accelerated radiation therapy and combination chemotherapy with paclitaxel).All patients were treated by 3 dimensional conformal radiotherapy,Thirty-seven patients in Group A received a f ractionated radiot herapy of 2 Gy daily,5 days per week,to the dose of 40 Gy or so,and then followed by LCHF radiotherapy:1.5Gy,twice daily,with the interval of more than 6 hours between fractions,to the total dose in the 61～70Gy for 6 weeks;Thirty-three patient in Group B were treated with the same fractionation as Group A,and ombination chemotherapy with paclitaxel with a dose of 135mg/m~2, once per 4 weeks.Results:sixty-one patients have been treated compeletly as the plan,and the difference of the short-term effect between the tow groups wasn't statistically significant(P＞0.05),but the difference of CR between the tow groups was statistically significant(P＜0.05 ),In the side effect,the myelosuppression of Group A is less than the Group B.Conclusion:late-course hyperfractionated accelerated radiation therapy and combination chemotherapy with paclitaxel for adenocarcinoma of lung can improve the CR in the short-term but not the total effficiency,and it can enhance the myelosuppression...